Close Menu

NEW YORK (360Dx) – Invivoscribe said this week that it has acquired additional contiguous space for its accredited Laboratories for Personalized Molecular Medicine — or LabPPMs — in San Diego, Japan, Germany, and China. The company also said it has bolstered its clinical diagnostic test offerings to include morphology, immunohistochemistry, flow cytometry, and multiparameter flow- and next-generation sequencing-based minimal residual disease testing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.